Showing results (11-20 of 57) with videos related to
Sort By:
Pageof 6
Journal of Inherited Metabolic Disease|June 14, 2014
Evaluation of an imaging biomarker, Dixon quantitative chemical shift imaging, in Gaucher disease: lessons learnedL van Dussen, E M Akkerman, C E M Hollak, et al.Blood Cells, Molecules & Diseases|June 21, 2014
Heterogeneous pattern of bone disease in adult type 1 Gaucher disease: clinical and pathological correlatesL van Dussen, P Lips, H W van Essen, et al.Drugs|July 29, 2017
Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic DiseasesY Schuller, C E M Hollak, C C Gispen-de Wied, et al.Journal of Inherited Metabolic Disease|October 4, 2007
Hypermetabolism in Gaucher disease type I is not associated with altered thyroid hormone levelsM Langeveld, E Endert, W M Wiersinga, et al.Molecular Genetics and Metabolism|January 22, 2013
A revised home treatment algorithm for Fabry disease: influence of antibody formationB E Smid, S L Hoogendijk, F A Wijburg, et al.Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|February 20, 2015
Unexplained left ventricular hypertrophy: consider a diagnosis of Fabry's diseaseG E Linthorst, A C Vedder, B J Bouma, et al.Nederlands Tijdschrift Voor Geneeskunde|October 15, 2005
[From gene to disease; Gaucher disease]C E M Hollak, R G Boot, B J H M Poorthuis, et al.Blood Cells, Molecules & Diseases|October 24, 2007
Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapyM Langeveld, M de Fost, J M F G Aerts, et al.Expert Opinion on Investigational Drugs|October 15, 2010
Pharmacological small molecules for the treatment of lysosomal storage disordersB E Smid, J M F G Aerts, R G Boot, et al.ESMO Open|April 8, 2023
Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countriesH C Post, T Schutte, M G H van Oijen, et al.Pageof 6